Table 2 P-values based on comparisons of the predicted FCO (%) between tumor and nontumor normal samples across different TCGA studies. P-values were obtained using a non-parametric Wilcoxon rank sum test, multiple linear regression model, and a non-parametric randomization-based testing procedure. P-values in PRAD are NA because FCO (%) in tumor and nontumor normal samples are both 0%

BLCA

1.60E-12

6.57E-08

0.00052

BRCA

3.60E-15

5.59E-22

<2E-05

CESC

4.30E-27

1.34E-51

<2E-05

CHOL

5.55E-06

8.63E-06

0.00016

COAD

7.23E-41

1.16E-61

<2E-05

ESCA

3.61E-11

2.21E-13

<2E-05

GBM

1.51E-23

7.94E-14

<2E-05

HNSC

4.52E-40

2.77E-58

<2E-05

KIRC

1.20E-68

9.05E-146

<2E-05

LIHC

9.65E-26

8.48E-17

<2E-05

LUAD

4.80E-12

0.00236

0.0216

LUSC

6.16E-34

2.78E-19

<2E-05

PAAD

0.00135

0.000307

0.00128

PRAD

NA

NA

NA

PCPG

0.396

3.84E-01

0.33

READ

7.62E-10

9.03E-09

0.00032

SARC

0.0254

0.00757

0.0607

STAD

3.64E-20

2.79E-13

<2E-05

THCA

4.47E-22

7.22E-26

<2E-05

UCEC

1.90E-37

2.32E-56

<2E-05